Clinical benefits of sequential administration of docetaxel and intermittent erlotinib as a second-line therapy for advanced non-small cell lung cancer (NSCLC): A phase II randomized study.
Francisco Aparisi
No relevant relationships to disclose
Alfredo Sanchez-Hernandez
No relevant relationships to disclose
Vicente Giner
No relevant relationships to disclose
José Muñoz-Langa
No relevant relationships to disclose
Gaspar Esquerdo
No relevant relationships to disclose
Antonio López Jiménez
No relevant relationships to disclose
Javier Garde
No relevant relationships to disclose
Jose Garcia Sanchez
No relevant relationships to disclose
Oscar Juan Vidal
No relevant relationships to disclose